ClinicalTrials.gg
CompletedNCT02448381Updated Apr 15, 2022Results posted

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

A Phase 3 interventional study of SGX301 (synthetic hypericin) and Placebo in Cutaneous T-Cell Lymphoma, sponsored by Soligenix. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.

Primary conditionMycosis FungoidesRegistry: Lymphoma, T-Cell, CutaneousReclassifiedWhy we changed it
Registry
Lymphoma, T-Cell, Cutaneous — the first condition term the registry derived for this study.
ClinicalTrials.gg
Mycosis Fungoides
Why
  1. The study's title name Mycosis Fungoides, a narrower term within Lymphoma, T-Cell, Cutaneous.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Soligenix · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Enrollment
17th of 279
169 · median 32
Started
2015
with 5 others
Phase 3
19 of 360
none open now
Registered
293rd of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 17th largest by enrollment of the 279 interventional ones that give a count, is one of 6 that started in 2015, is one of 19 in phase 3, and was the 293rd registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

03

Conditions studied

  • Cutaneous T-Cell Lymphoma

Browse trials for

Keywords

  • CTCL
  • Mycosis fungoides
  • Hypericin
  • SGX301
  • MF
04

In context

Mycosis Fungoides Reclassified

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

This study's enrollment of 169 is above the median of 34 across 321 interventional studies indexed under Mycosis Fungoides.

Browse Mycosis Fungoides studies →

Lead sponsor

Soligenix is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Compared within Mycosis Fungoides, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, T-Cell, Cutaneous. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA.
  • Subjects must have a minimum of three (3) evaluable, discrete lesions.
  • Subjects must be willing to refrain from sunbathing for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History of sun and photosensitive dermatoses including porphyria, systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous light eruptions or radiation therapy within 30 days of enrolling.
  • Pregnancy or mothers who are breast feeding.
  • Males and females not willing to use effective .
  • Unhealed sunburn.
  • Subjects receiving topical or other topical treatments for CTCL within 2 weeks.
  • Subjects receiving systemic steroids, nitrogen mustard, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment.
  • Subjects with significant history of systemic due to drugs or infection with or HTLV 1.
  • Subjects taking other drugs or drugs of abuse within 30 days of entry into this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
169 participants (actual)

Study arms

  • Active comparator
    SGX301

    Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy. Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated. Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment. Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index).

    Drug: SGX301 (synthetic hypericin)

  • Placebo comparator
    Placebo

    Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.

    Drug: Placebo

Interventions

  • DrugSGX301 (synthetic hypericin)

    0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.

    Also known as: Hypericin, Synthetic Hypericin

  • DrugPlacebo

    USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.

07

What researchers measure

Primary outcomes

  1. Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo

    The percentage of patients achieving a treatment response in each of the 2 treatment groups. A treatment response was defined as a ≥50% improvement in CAILS score at Week 8 when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome. The overall CAILS score was calculated by adding the total score as described above for each of the 3 lesions. The overall CAILS score has a range of 0 to 111. A lower score means a better outcome.

    Time frame: 8 weeks

Secondary outcomes

  1. Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score (Cycle 1 and 2 SGX301 vs Cycle 1 Placebo)

    The percentage of patients achieving a treatment response at Week 16 that received SGX301 for both Cycle 1 and 2 compared to the response rate in patients that received Placebo in Cycle 1. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

    Time frame: 16 weeks

  2. Number of Responders and Non-Responders With a Treatment Response of 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score in Patients Who Received 3 Cycles of SGX301

    The percentage of patients achieving a treatment response at Week 24 compared at Week 16 in SGX301 treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

    Time frame: 24 weeks

  3. Patch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)

    The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

    Time frame: 16 weeks

  4. Plaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)

    The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

    Time frame: 16 weeks

08

Results

Posted Apr 15, 2022

Participant flow

Participant flow — Overall Study
MilestoneSGX301Placebo
Started11851
Randomized, not treated21
Cycle 111650
Cycle 211045
Cycle 37832
Follow-up period9839
Completed8332
Not completed3519
Withdrew: Adverse event20
Withdrew: Lost to follow-up169
Withdrew: Physician decision11
Withdrew: Pregnancy10
Withdrew: Withdrawal by subject139
Withdrew: Noncompliance with study procedures20

Outcome measures

PrimaryNumber of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo

The percentage of patients achieving a treatment response in each of the 2 treatment groups. A treatment response was defined as a ≥50% improvement in CAILS score at Week 8 when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome. The overall CAILS score was calculated by adding the total score as described above for each of the 3 lesions. The overall CAILS score has a range of 0 to 111. A lower score means a better outcome.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo
ParticipantsSGX301Placebo
Responder192
Non-responder9748
Statistical analysis
  • SGX301 vs Placebo · Regression, Logistic · p = 0.04
SecondaryNumber of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score (Cycle 1 and 2 SGX301 vs Cycle 1 Placebo)

The percentage of patients achieving a treatment response at Week 16 that received SGX301 for both Cycle 1 and 2 compared to the response rate in patients that received Placebo in Cycle 1. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score (Cycle 1 and 2 SGX301 vs Cycle 1 Placebo)
ParticipantsSGX301 (Cycle 1 & 2 = SGX301)Placebo (Cycle 1)
Responder442
Non-responder6648
Statistical analysis
  • SGX301 (Cycle 1 & 2 = SGX301) vs Placebo (Cycle 1) · Regression, Logistic · p = <0.0001
SecondaryNumber of Responders and Non-Responders With a Treatment Response of 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score in Patients Who Received 3 Cycles of SGX301

The percentage of patients achieving a treatment response at Week 24 compared at Week 16 in SGX301 treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Responders and Non-Responders With a Treatment Response of 3 Treated Lesions as Measured by the Composite Assessment of Index Lesion Disease Severity (CAILS) Score in Patients Who Received 3 Cycles of SGX301
ParticipantsSGX301 (Cycle 1, 2 & 3 = SGX301)
Responder38
Non-responder40
Statistical analysis
  • SGX301 (Cycle 1, 2 & 3 = SGX301) · McNemar · p = 0.046
SecondaryPatch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)

The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

Time frame:
16 weeks
Reported as:
Number · lesions with response
Patch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)
lesions with responseSGX301 (Cycle 1 & 2 = SGX301)Placebo (Cycle 1)
Patch Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)6514
Statistical analysis
  • SGX301 (Cycle 1 & 2 = SGX301) vs Placebo (Cycle 1) · Fisher Exact · p = =0.0009
SecondaryPlaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)

The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described.

Time frame:
16 weeks
Reported as:
Number · lesions with response
Plaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)
lesions with responseSGX301 (Cycle 1 & 2 = SGX301)Placebo (Cycle 1)
Plaque Lesion Response Rates With Extended Treatment (Cycle 1 & 2 SGX301 vs Cycle 1 Placebo)647
Statistical analysis
  • SGX301 (Cycle 1 & 2 = SGX301) vs Placebo (Cycle 1) · Fisher Exact · p = <0.0001

Adverse events

Collected over From the first dose of study drug (SGX301 or Placebo) until 1 month following the participant's last evaluation visit (Cycle 1 = 8 weeks, Cycle 2 = 16 weeks, Cycle 3 = 24 weeks). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cycle 1 - SGX3010/116 (0%)1/116 (0.9%)56/116 (48.3%)
Cycle 1 - Placebo0/50 (0%)1/50 (2%)26/50 (52%)
Cycle 2 - SGX3010/155 (0%)0/155 (0%)66/155 (42.6%)
Cycle 3 - SGX3010/110 (0%)3/110 (2.7%)49/110 (44.5%)
Overall SGX3010/161 (0%)4/161 (2.5%)108/161 (67.1%)
Most frequent serious events
Most frequent serious events
EventCycle 1 - SGX301Cycle 1 - PlaceboCycle 2 - SGX301Cycle 3 - SGX301Overall SGX301
AngioedemaSkin and subcutaneous tissue disorders0/1161/500/1550/1100/161
Gallbladder obstructionHepatobiliary disorders0/1160/500/1551/1101/161
CholecystitisHepatobiliary disorders0/1160/500/1551/1101/161
PneumoniaInfections and infestations0/1160/500/1551/1101/161
Gastritis alcoholicGastrointestinal disorders1/1160/500/1550/1101/161
Most frequent other events
Showing 10 of 21
Most frequent other events
EventCycle 1 - SGX301Cycle 1 - PlaceboCycle 2 - SGX301Cycle 3 - SGX301Overall SGX301
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders9/1161/505/1555/11017/161
Application site painGeneral disorders8/1162/505/1556/11016/161
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications6/1162/504/1555/11014/161
Upper respiratory tract infectionInfections and infestations8/1164/502/1552/11012/161
PruritusSkin and subcutaneous tissue disorders6/1162/502/1555/11012/161
Viral upper respiratory tract infectionInfections and infestations4/1160/504/1554/11011/161
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders3/1163/506/1554/11011/161
HeadacheNervous system disorders5/1163/505/1552/11010/161
Application site pruritusGeneral disorders5/1161/505/1550/1109/161
Application site paraesthesiaGeneral disorders6/1160/502/1552/1107/161

Baseline characteristics

The baseline analysis population was defined as all participants that were treated with at least one dose of treatment (SGX301 or Placebo)

Age, Continuous
Age, Continuous(years)SGX301PlaceboTotal
Mean57.9 ± 15.9459.4 ± 16.2658.4 ± 16.00
Sex: Female, Male
Sex: Female, Male(Participants)SGX301PlaceboTotal
Female472370
Male692796
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SGX301PlaceboTotal
Hispanic or Latino10313
Not Hispanic or Latino10345148
Unknown or Not Reported325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SGX301PlaceboTotal
White8436120
Black or African American271239
Asian404
Native Hawaiian or Other Pacific Islander000
American Indian or Alaska Native000
Other022
Unknown101
09

Study locations

33 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • University of Arizona
    Phoenix, Arizona 85004, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • University of Arkansas
    Little Rock, Arkansas 72205, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • Leon Medical Research
    Miami, Florida 33015, United States
  • Medical Professional Clinical Research
    Miami, Florida 33165, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University
    Chicago, Illinois 60612, United States
  • Dawes Fretzin Dermatology Group
    Indianapolis, Indiana 46256, United States
  • Tulane University
    New Orleans, Louisiana 70112, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Rochester Skin Lymphoma Medical Group
    Fairport, New York 14450, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Stony Brook Medicine
    Stony Brook, New York 11790, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson Dermatology
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29424, United States
  • Vanderbilt University
    Nashville, Tennessee 37212, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • INOVA Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23502, United States
  • Seattle Care Cancer Center
    Seattle, Washington 98109, United States
10

References and documents

Publications

  • Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022 Sep 1;158(9):1031-1039. doi: 10.1001/jamadermatol.2022.2749. PubMed 35857290 ↗
  • Valipour A, Jager M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD008946. doi: 10.1002/14651858.CD008946.pub3. PubMed 32632956 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Jun 2020, 54 months.

Results were first posted in Apr 2022, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2015
First posted
May 19, 2015
StartActual
Dec 2015
Primary completionActual
Jun 2020
CompletionActual
Nov 2020
Results first posted
Apr 15, 2022
Last update
Apr 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02448381
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
May 19, 2015
Start date
Dec 2015
Primary completion
Jun 2020
Completion
Nov 2020
Results posted
Apr 15, 2022
Last update
Apr 15, 2022
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion